Generation Bio Co. (GBIO)
Stock Price:
$30.11 USD
2.73 (9.97%)
Updated Sep 25, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.40B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
n/a |
| Shares Out |
46.43M |
| EPS (ttm) |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Sep 25, 2020 |
| Last Price |
$30.11 |
| Previous Close |
$27.38 |
| Change ($) |
2.73 |
| Change (%) |
9.97% |
| Day's Open |
27.31 |
| Day's Range |
27.31 - 30.40 |
| Day's Volume |
222,012 |
| 52-Week Range |
17.00 - 32.18 |
More Stats
| Market Cap |
1.40B |
| Enterprise Value |
1.10B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
46.43M |
| Float |
29.63M |
| EPS (basic) |
n/a |
| EPS (diluted) |
n/a |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
646,964 |
| Short Ratio |
5.01 |
| Short % of Float |
1.79% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
4.18 |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
n/a |
| Free Cash Flow |
n/a |
| Net Cash |
301.09M |
| Net Cash / Share |
6.49 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$32.67*
(8.50% upside)
Low
29.0
Current: $30.11
High
38.0
Target: 32.67
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | 0.04 |
| Gross Profit | - | 0.04 |
| Operating Income | -62.30 | -37.29 |
| Net Income | -61.32 | -35.80 |
| Shares Outstanding | 4.73 | 3.35 |
| Earnings Per Share | -12.96 | -10.69 |
| Operating Cash Flow | -40.35 | -28.12 |
| Capital Expenditures | -19.91 | -3.02 |
| Free Cash Flow | -60.25 | -31.14 |
| Cash & Equivalents | 15.13 | 74.92 |
| Net Cash / Debt | 15.13 | 74.92 |
| Assets | 42.14 | 83.52 |
| Liabilities | 25.14 | 9.52 |
| Book Value | -98.59 | -41.59 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Generation Bio Co. |
| Country |
United States |
| CEO |
Cameron Geoffrey McDonough |
Stock Information
| Ticker Symbol |
GBIO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GBIO |
| IPO Date |
June 12, 2020 |
Description
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of eight programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.